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OBJECTIVES This study evaluated clinical outcomes in patients with acute myocardial infarction (MI)
treated with fibrinolytic therapy in hospitals with and without coronary revascularization
capability.
BACKGROUND Patients with MI may have better outcomes when admitted to certain hospitals with coronary
revascularization capability. Development of regional heart care centers for the treatment of
MI has been proposed.
METHODS We performed a retrospective analysis of 25,515 U.S. patients enrolled in the Global Use of
Streptokinase and TPA (alteplase) for Occluded Coronary arteries (GUSTO)-I trial.
Outcomes of patients admitted to hospitals with and without coronary revascularization
capability were analyzed. We also analyzed patients who remained in hospitals without
coronary revascularization capability compared with those transferred to hospitals with
revascularization capability.
RESULTS Baseline characteristics and complications were similar between patients in the two hospital
types. Patients in hospitals with coronary revascularization capability more often underwent
cardiac catheterization (78.1% vs. 59.2%; p  0.001), angioplasty (34.6% vs. 22.6%; p 
0.001), or bypass surgery (14.1% vs. 10.4%; p  0.001) but had a similar adjusted 30-day
(odds ratio [OR] 0.91, 95% confidence interval [CI] 82 to 1.02) and one-year (OR 0.98, 95%
CI 0.90 to 1.07) mortality. Forty percent of patients admitted to hospitals without
revascularization capability were transferred, with 94% of transfer patients undergoing
angiography. Almost 80% of transfers occurred 48 h after hospital admission.
CONCLUSIONS Patients receiving fibrinolytic therapy for acute MI admitted to hospitals without coronary
revascularization capability appear to have outcomes similar to those of patients admitted to
hospitals with such capability when aspirin and beta-adrenergic blocking agents are given
appropriately and transfer is available for angiography and angioplasty as needed. (J Am
Coll Cardiol 2002;40:1034–40) © 2002 by the American College of Cardiology Foundation
Most patients with acute myocardial infarction (MI) are
treated in community hospitals without coronary revascu-
larization capability, but several recent retrospective studies
have suggested that patients admitted to tertiary care hos-
pitals capable of performing these procedures have better
clinical outcomes (1–5). Similarly, small randomized trials
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of primary percutaneous transluminal coronary angioplasty
(PTCA) versus fibrinolytic therapy have shown better out-
comes with PTCA, a treatment available only at tertiary
care hospitals (6). Other studies have shown improved
quality of life, but no survival advantage, with a treatment
strategy using more invasive procedures (7–9), although one
study did relate higher procedure rates in the U.S. versus
Canada to a trend of better survival (10). These reports raise
the question of whether routine transfer of patients to
hospitals with coronary revascularization capability would
improve outcomes.
The Global Utilization of Streptokinase and t-PA for
Occluded Coronary Arteries (GUSTO-I) trial prospectively
enrolled 41,021 patients with MI treated with fibrinolytic
therapy in 1,081 hospitals in 15 countries (11,12). To
evaluate the concept of regional heart-care centers further,
we limited our analysis in this study to the patients enrolled
in U.S. hospitals. Our purpose was to examine clinical
outcomes in patients treated at hospitals with and without
coronary revascularization capability. Additionally, we eval-
uated outcomes in patients who remained in hospitals
without coronary revascularization capability compared
with those transferred to hospitals with revascularization
capability.
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METHODS
Study population. There were 25,515 patients from 660
U.S. hospitals enrolled in GUSTO-I between December
27, 1990, and February 22, 1993, with site information
available. The details and primary end points of GUSTO-I
have previously been reported (11,12). Briefly, patients with
chest pain lasting 20 min but 6 h with ST-segment
elevation in two contiguous electrocardiographic leads, and
no contraindications for fibrinolytic therapy, were random-
ized to one of four fibrinolytic regimens: streptokinase (1.5
million U over 1 h) with intravenous heparin, streptokinase
with subcutaneous heparin, accelerated alteplase (15-mg
bolus followed by infusion at 0.75 mg/kg [50 mg] over 30
min and 0.5 mg/kg [35 mg] over the next hour) with
intravenous heparin, or alteplase (1 mg/kg over 1 h [90
mg]) plus streptokinase (1 million U over 1 h) with
intravenous heparin. Adjunctive therapy included 160 mg
chewable aspirin as soon as possible followed by 160 to 325
mg/day. Subcutaneous heparin (12,500 U twice daily) was
continued for seven days or until discharge. Intravenous
heparin (5,000 U bolus, then 1,000 U/h, adjusted to
maintain an activated partial thromboplastin time of 60 s to
85 s) was given for 48 h. Unless contraindicated, 10 mg
intravenous atenolol was given in two divided doses fol-
lowed by 50 to 100 mg/day orally. All other medications
and invasive procedures were left to the discretion of the
attending physician. The primary end point of the trial was
all-cause mortality at 30 days.
Definitions. Hospital types were divided into those that
performed PTCA and coronary artery bypass graft surgery
(CABG) (n  286) and those without coronary revascular-
ization programs (n 374). Recurrent ischemia was defined
as symptoms, electrocardiogram changes, and/or new hypo-
tension, pulmonary edema, or murmur thought by the
physician to represent myocardial ischemia. Reinfarction
was defined as the presence of 2 of the following:
recurrent ischemia 15 min duration, new ST- or T-wave
changes or new Q-waves, a second elevation in cardiac
enzymes above the upper limit of normal or by another 20%
if already elevated, or angiographic occlusion of a previously
documented patent coronary artery. Cardiogenic shock was
defined as systolic blood pressure (BP) 90 mm Hg for 1
h that was not responsive to fluid administration alone,
thought to be secondary to cardiac dysfunction, and associ-
ated with signs of hypoperfusion or a cardiac index 2.2
l/min/m2.
Patient transfers were listed on the case report form as
elective, emergency, or required for participation in the
angiographic substudy (12). Patients transferred to hospitals
with coronary revascularization capability within 6 h were
assumed to be transferred primarily for rescue PTCA.
Patients transferred between 6 h and 48 h were assumed to
be transferred generally for treatment of recurrent ischemia
or infarction. Finally, patients transferred after 48 h of
admission were assumed to be transferred generally for
elective procedures.
Data collection. Baseline demographics, medical history,
medications, procedures, complications, and clinical events
were collected prospectively on the case report form. A
blinded central clinical events committee adjudicated all
suspected strokes using prospectively defined criteria.
Data analysis. All analyses were performed with SAS
software (SAS, Cary, North Carolina). Prospectively de-
fined baseline and end point variables were compared within
the analysis groups using a Pearson chi-square test for
categorical variables and a Wilcoxon rank-sum test for
continuous variables. All categorical measures are reported
as counts with percentages. All continuous measures are
reported as medians for measures of centrality and 25th and
75th percentiles as measures of variation.
A previously validated and published model of 30-day
death (13) found several factors statistically significant in a
multivariable model. However, five of these factors (age,
systolic BP, heart rate, Killip class, and MI location) jointly
made up approximately 90% of the total chi-square (13);
therefore, these five factors are used as the baseline factors
for adjustment. We also tested all factors from the published
model, and no differences in interpretations were found, so
only models using the main five factors as confounders are
reported.
Logistic regression modeling was used to assess the
relationship between each of the groups (transfer status and
revascularization capability) and death after adjusting for the
five baseline factors. This process was used for both 30-day
and one-year mortality. The interactions of each of the five
factors with the groups were also tested to see if the
association of transfer status (or revascularization capability)
and mortality changed according to the levels of the baseline
variables. Age, systolic BP, and heart rate were used as
continuous measures in both the main effects and interac-
tion terms. The continuous variables that were found to
have statistically significant interactions were divided into
two discrete groups for descriptive purposes only. The
unadjusted rates of mortality within the baseline and anal-
ysis subgroups are generated to illustrate the differential
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CABG  coronary artery bypass grafting
CI  confidence interval
GUSTO-I  Global Utilization of Streptokinase and
TPA (alteplase) for Occluded coronary
arteries
GUSTO-IIb  Global Use of Strategies To Open
occluded arteries in acute coronary
syndromes
MI  myocardial infarction
NRMI  National Registry of Myocardial
Infarction
OR  odds ratio
PTCA  percutaneous transluminal coronary
angioplasty
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association. The odds ratios (OR) with 95% confidence
intervals (CI) illustrate the adjusted interactions.
A p value 0.01 instead of 0.05 was considered
statistically significant because of the large numbers of
patients and the multiple comparisons.
RESULTS
Baseline characteristics. Patients treated at hospitals with
coronary revascularization capability were significantly
younger than those treated at hospitals without revascular-
ization capability (Table 1). There were no significant
differences in gender, Killip class, hypertension, diabetes
mellitus, smoking, dyslipidemia, family history of coronary
disease, or prior stroke. Patients treated at hospitals with
coronary revascularization capability had a higher incidence
of prior angina, MI, PTCA, and CABG.
Patients transferred from hospitals without coronary re-
vascularization capability were younger, were more often
male, and had a higher incidence of hypertension, dyslipi-
demia, prior angina, and prior PTCA than patients not
transferred (Table 1). There were no differences in Killip
class or history of diabetes, smoking, MI, stroke, or CABG
between the two groups.
Medical treatment. The use of aspirin, intravenous ni-
trates, calcium-channel blockers, digitalis, and intravenous
inotropic agents was significantly greater in patients treated
at hospitals with revascularization capability, although the
absolute difference was only 1% for the use of aspirin (Table
2). Oral beta-adrenergic blocking agents were used slightly
more often in patients treated at hospitals without revascu-
larization capability. There were no differences in the use of
oral or topical nitrates, intravenous beta-blockers, or
angiotensin-converting enzyme (ACE) inhibitors. The use
of all medications was higher in patients transferred from
hospitals without coronary revascularization capability than
in patients not transferred.
Complications. The incidence of most complications after
MI was similar in the two types of hospitals (Table 3).
Second- or third-degree atrioventricular block occurred
more often, whereas acute mitral regurgitation occurred less
often, in patients treated at hospitals with revascularization
capability.
Patients transferred from hospitals without revasculariza-
tion capability had a higher incidence of atrial fibrillation or
flutter and acute mitral regurgitation, and a lower incidence
of asystole, than patients not transferred (Table 3). There
Table 1. Baseline Characteristics
Characteristics
Hospitals With
Revascularization
Capability
(n  12,279)
Hospitals Without
Revascularization
Capability
(n  13,236) p Value
Transfer Patients
(n  5,218)
Non-Transfer Patients
(n  8,018) p Value
Age (yrs) 60.7 (51.4, 69.5) 61.4 (51.8, 70) 0.002 60.4 (51.1, 68.7) 62.1 (52.3, 70.9) 0.0001
Male 8,980 (73.2%) 9,682 (73.2%) 0.97 3,898 (74.8%) 5,784 (72.2%) 0.001
Killip class  III 232 (1.9%) 251 (1.9%) 0.99 85 (1.6%) 166 (2.1%) 0.07
Hypertension 5,172 (42.3%) 5,404 (41.0%) 0.04 2,204 (42.4%) 3,200 (40.1%) 0.008
Diabetes 1,981 (16.2%) 2,172 (16.5%) 0.55 820 (15.7%) 1,352 (16.9%) 0.074
Current smoking 5,315 (43.5%) 5,589 (42.5%) 0.08 2,165 (41.6%) 3,424 (43.0%) 0.11
Elevated cholesterol 4,511 (37.8%) 4,618 (36.4%) 0.02 2,021 (40.2%) 2,597 (33.9%) 0.001
Family history CAD 5,712 (48.7%) 5,987 (47.9%) 0.18 2,497 (50.4%) 3,490 (46.2%) 0.001
Prior angina 4,513 (37.0%) 4,482 (34.1%) 0.001 1,899 (36.6%) 2,583 (32.4%) 0.001
Prior infarction 2,181 (17.8%) 2,165 (16.4%) 0.003 864 (16.6%) 1,301 (16.3%) 0.64
Prior stroke 281 (2.3%) 307 (2.3%) 0.88 113 (2.2%) 194 (2.4%) 0.34
Prior angioplasty 752 (6.1%) 589 (4.5%) 0.001 282 (5.4%) 307 (3.8%) 0.001
Prior bypass surgery 783 (6.4%) 601 (4.6%) 0.001 251 (4.8%) 350 (4.4%) 0.24
CAD  coronary artery disease.
Table 2. Treatments Received
Drug Therapies
Hospitals With
Revascularization
Capability
Hospitals Without
Revascularization
Capability p Value
Transfer
Patients
Non-Transfer
Patients p Value
Aspirin 11,399 (93.3%) 12,119 (92.3%) 0.002 4,881 (94.5%) 7,238 (90.9%) 0.001
Intravenous nitrates 10,803 (88.1%) 10,507 (79.6%) 0.001 4,578 (88.1%) 5,929 (74.0%) 0.001
Oral or topical nitrates 8,715 (71.1%) 9,351 (71.1%) 0.94 3,921 (76.1%) 5,430 (67.9%) 0.001
Intravenous beta-blockers 6,560 (53.5%) 6,913 (52.3%) 0.06 2,852 (54.9%) 4,061 (50.7%) 0.001
Oral beta-blockers 8,980 (73.2%) 9,894 (75.0%) 0.002 3,945 (76.0%) 5,949 (74.3%) 0.021
Calcium-channel blockers 4,735 (38.6%) 4,409 (33.5%) 0.001 2,244 (43.5%) 2,165 (27.1%) 0.001
ACE inhibitors 2,559 (20.9%) 2,647 (20.2%) 0.15 1,088 (21.2%) 1,559 (19.5%) 0.016
Digitalis 2,199 (17.9%) 1,947 (14.8%) 0.001 949 (18.4%) 998 (12.5%) 0.001
Other inotropic agents 3,027 (24.7%) 2,669 (20.3%) 0.001 1,241 (24.1%) 1,428 (17.9%) 0.001
ACE  angiotensin-converting enzyme.
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were no differences in atrioventricular block, ventricular
arrhythmias, acute ventricular septal rupture, cardiac tam-
ponade, or Killip class.
Procedures. Patients at hospitals with coronary revascular-
ization capability were more likely to undergo mechanical
ventilation, pulmonary artery catheterization, temporary
pacemaker placement, intra-aortic balloon counterpulsa-
tion, angiography, PTCA, and CABG (Table 4).
Patients transferred from hospitals without coronary re-
vascularization capability almost always had angiography
and more often underwent other invasive procedures (Table
4). Patients remaining in such hospitals were less likely to
undergo an invasive procedure. The indication for angiog-
raphy was available in 4,847 of 5,218 patients; it was
performed emergently in 1,006 patients (20.8%), electively
in 3,681 (75.9%), and as required by the angiographic
substudy protocol in 160 patients (3.3%). Similarly, data
were available for 3,325 of 5,218 patients regarding time to
transfer: 206 patients (6.2%) were transferred within 6 h,
496 (14.9%) between 6 h and 48 h, and the remaining 2,623
(78.9%) after 48 h.
Clinical events. The rates of recurrent ischemia, reinfarc-
tion, congestive heart failure, shock, and stroke did not
differ between the two hospital types (Table 5). Patients in
hospitals with revascularization capability had 30-day mor-
tality risk similar to that of patients in hospitals without
revascularization capability (OR 0.90, 95% CI 0.82 to 1.0).
After adjustment for age, systolic BP, heart rate, baseline
Killip class, and MI location, 30-day mortality remained
similar for patients treated at hospitals with revasculariza-
tion capability compared with those treated at hospitals
without revascularization capability (OR 0.91, 95% CI 82 to
1.02). The unadjusted (OR 0.96, 95% CI 0.89 to 1.05) and
adjusted (OR 0.98, 95% CI 0.90 to 1.07) one-year mortality
rates were also similar between the two hospital types. The
30-day (adjusted OR 0.95, 95% CI 0.79 to 1.14) and
one-year (adjusted OR 1.06, 95% CI 0.91 to 1.23) mortality
rates were similar among patients 65 years of age treated
at hospitals with revascularization capability compared with
those treated at hospitals without revascularization capabil-
ity. Likewise, the 30-day (adjusted OR 0.90, 95% CI 0.79 to
1.02) and one-year (adjusted OR 0.94, 95% CI 0.85 to 1.05)
mortality rates were similar among patients65 years of age
treated at hospitals with revascularization capability com-
pared with those treated at hospitals without revasculariza-
tion capability.
Patients transferred from hospitals without revasculariza-
tion capability had a higher incidence of recurrent ischemia,
recurrent infarction, and congestive heart failure than non-
transfer patients but equivalent rates of shock and stroke
(Table 5). Unadjusted 30-day (OR 0.38, 95% CI 0.32 to
0.44) and one-year (OR 0.46, 95% CI 0.40 to 0.52)
mortality rates were significantly lower for transfer patients.
After adjustment for differences in baseline predictors of
30-day and one-year mortality, these still remained signif-
icantly lower for transfer versus non-transfer patients ([OR
Table 3. Complications
Complications
Hospitals With
Revascularization
Capability
Hospitals Without
Revascularization
Capability p Value
Transfer
Patients
Non-Transfer
Patients p Value
Anaphylactic reaction 80 (0.7%) 69 (0.5%) 0.18 35 (0.7%) 34 (0.4%) 0.052
Sustained hypotension 1,703 (13.9%) 1,794 (13.6%) 0.51 679 (13.1%) 1,115 (13.9%) 0.18
Atrioventricular block* 1,199 (9.8%) 1,121 (8.5%) 0.001 447 (8.6%) 674 (8.4%) 0.68
Sustained ventricular tachycardia 794 (6.5%) 948 (7.2%) 0.02 391 (7.5%) 557 (7.0%) 0.20
Ventricular fibrillation 866 (7.1%) 943 (7.2%) 0.77 390 (7.5%) 553 (6.9%) 0.18
Asystole 795 (6.5%) 883 (6.7%) 0.49 204 (3.9%) 679 (8.5%) 0.001
Atrial fibrillation/flutter 1,272 (10.4%) 1,334 (10.1%) 0.50 614 (11.9%) 720 (9.0%) 0.001
Acute mitral regurgitation 194 (1.6%) 267 (2.0%) 0.008 131 (2.5%) 136 (1.7%) 0.001
Acute ventricular septal rupture 72 (0.6%) 81 (0.6%) 0.78 42 (0.8%) 39 (0.5%) 0.020
Cardiac tamponade 111 (0.9%) 92 (0.7%) 0.06 34 (0.7%) 58 (0.7%) 0.65
Worst Killip class  III 1,158 (9.5%) 1,212 (9.2%) 0.45 487 (9.5%) 725 (9.1%) 0.44
*Second- or third-degree.
Table 4. Procedures Performed
Procedures
Hospitals With
Revascularization
Capability
Hospitals Without
Revascularization
Capability p Value
Transfer
Patients
Non-Transfer
Patients p Value
Ventilator 2,252 (18.4%) 1,721 (13.1%) 0.001 1,185 (23.0%) 536 (6.7%) 0.001
Defibrillation 1,296 (10.6%) 1,335 (10.1%) 0.26 598 (11.6%) 737 (9.2%) 0.001
Pulmonary artery catheter 2572 (21.0%) 2,004 (15.2%) 0.001 1,428 (27.7%) 576 (7.2%) 0.001
Pacemaker 1,321 (10.8%) 1,104 (8.4%) 0.001 664 (12.9%) 440 (5.5%) 0.001
Intra-aortic balloon pump 772 (6.3%) 607 (4.6%) 0.001 483 (9.4%) 124 (1.6%) 0.001
Cardiac catheterization 9,570 (78.1%) 7,809 (59.2%) 0.001 4,873 (94.1%) 2,936 (36.7%) 0.001
Angioplasty 4,252 (34.6%) 2,993 (22.6%) 0.001 2,439 (46.7%) 554 (6.9%) 0.001
Bypass surgery 1,732 (14.1%) 1,363 (10.4%) 0.001 1,198 (23.2%) 165 (2.1%) 0.001
1037JACC Vol. 40, No. 6, 2002 Mehta et al.
September 18, 2002:1034–40 MI Outcomes by Hospital Type
0.45, 95% CI 0.38 to 0.54] and [OR 0.54, 95% CI 0.47 to
0.63], respectively). These results are probably biased by the
fact that patients who died early were obviously not candi-
dates for transfer. The excess of asystolic events (679 vs.
204, p  0.001) in the non-transfer group supports this
hypothesis. Similarly, mortality at 30-days and one-year was
significantly lower in both transfer patients age 65 and
65 years.
DISCUSSION
In this large study, patients with acute MI treated with
fibrinolytic therapy and admitted to hospitals with and
without coronary revascularization capability had similar
outcomes when appropriate candidates received aspirin and
beta-blockers, and immediate transfer was available for
angiography and angioplasty as needed. Although the non-
significant lower 30-day adjusted mortality in hospitals with
coronary revascularization capability does not exclude a
modestly better outcome in these hospitals, lack of substan-
tial advantage is more likely, given the one-year results.
Further, there was no difference in 30-day and one-year
mortality between the two hospital types in patients age
65 or 65 years. These results are consistent with prior
observations that immediate availability of invasive proce-
dures is not associated with a survival advantage (4,14–19).
Hospitals with and without coronary revascularization
capability. Although there were a few statistically signifi-
cant differences in baseline characteristics and complications
due to the large sample size, there were no major clinical
differences in patients admitted to hospitals with and
without coronary revascularization capability. This would be
expected given the current practice of transporting patients
to the nearest hospital for chest pain evaluation. There was
a statistically and clinically significant increase in number of
procedures performed at hospitals with revascularization
capability, however, as has been documented previously
(14,15,20,21).
Better outcomes have been shown for patients with MI
treated at teaching hospitals (1,3,5), at top-ranked hospitals
(2), and by cardiologists (22–24). Additionally, higher
physician volume (24), primary PTCA volume (25), and
hospital volume (4) predict better outcomes for patients
with MI. Patients in these situations are more likely to be
treated with medications associated with improved survival
(aspirin, beta-blockers, and ACE inhibitors) (2,5) and with
interventional procedures performed by highly skilled
teams. These different descriptors most likely represent
important measures of quality of care.
Kizer et al. (26) found that physicians who design or
implement randomized clinical trials are more likely to use
aspirin, beta-blockers, and ACE inhibitors than physicians
in routine clinical practice. Patients in this study enrolled in
hospitals without revascularization capability were treated
with the same protocol as were patients enrolled in hospitals
with revascularization capability, and they had similar clin-
ical outcomes, including 30-day and one-year mortality,
despite undergoing fewer procedures. These results suggest
that the ability to successfully implement a randomized
clinical trial protocol or to follow an evidence-based MI
treatment protocol should represent another measure of
quality of care.
Interhospital transfer. Most previous observational data-
base studies analyzing discharge diagnoses have excluded
transfer patients (4,5,24). Likewise, patients admitted as
transfers from other hospitals were omitted from the second
National Registry of Myocardial Infarction (NRMI-2) anal-
yses (15,25). In this study, 40% of patients treated with
fibrinolytic therapy in hospitals without revascularization
capability were transferred to hospitals with this capability.
Eighty percent of the transfers occurred 48 h after
hospital admission; fewer than 10% of transfers occurred
within a time window where rescue PTCA might be
performed. The overwhelming indication for transfer ap-
peared to be referral for angiography, which was performed
in 94% of patients. Ischemic complications, not cardiogenic
shock or ventricular arrhythmias, were more common in
these patients.
Transfer patients received more pharmacologic therapy,
underwent more procedures, and had lower unadjusted and
adjusted mortality rates than patients who were not trans-
ferred. They were a selected group of patients, however.
Most had survived the initial 24 h of hospitalization, within
which 40% of the deaths occurred in this study (27). Thus,
immediate treatment with fibrinolytic therapy along with
other appropriate medical regimens, initial stabilization,
early risk stratification, and selective referral by physicians at
Table 5. Clinical Events
Events
Hospitals With
Revascularization
Capability
Hospitals Without
Revascularization
Capability p Value
Transfer
Patients
Non-Transfer
Patients p Value
Recurrent ischemia 2,728 (22.3%) 3,034 (23.0%) 0.14 1,783 (34.4%) 1,251 (15.7%) 0.001
Reinfarction 457 (3.7%) 517 (3.9%) 0.42 338 (6.5%) 179 (2.2%) 0.001
Congestive heart failure 2,176 (17.8%) 2,387 (18.1%) 0.46 997 (19.3%) 1,390 (17.4%) 0.006
Shock 833 (6.8%) 881 (6.7%) 0.71 354 (6.8%) 527 (6.6%) 0.60
Stroke 187 (1.5%) 199 (1.5%) 0.91 72 (1.4%) 127 (1.6%) 0.36
In-hospital mortality 766 (6.2%) 903 (6.8%) 0.06 184 (3.5%) 719 (9.0%) 0.001
30-day mortality 802 (6.6%) 949 (7.2%) 0.04 196 (3.8%) 753 (9.4%) 0.001
One-year mortality 1,177 (9.6%) 1,313 (9.9%) 0.37 318 (6.1%) 995 (12.4%) 0.001
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hospitals without coronary revascularization capability ap-
peared to produce outcomes similar to those achieved in
hospitals where revascularization was available, with fewer
procedures performed.
On-site cardiac catheterization facility. No difference in
mortality has been reported for patients treated at hospitals
with on-site cardiac catheterization facilities (4,14–19) or in
geographic regions with higher rates of intervention
(7,10,28,29). Moreover, Canto et al. (25) found 28% lower
mortality among patients who underwent primary PTCA at
hospitals with high volumes versus hospitals with low
volumes, but no relationship between volume of fibrinolytic
interventions and hospital mortality. Our results are similar
to these findings and support the concept that as long as
access to PTCA or CABG is available, it need not be
immediately available to maintain the initial benefits of
fibrinolysis.
Although older randomized trials found superiority for
PTCA over streptokinase (30) and over 3-h alteplase
infusions (31), when time to treatment was 1 h, no
mortality benefit was seen in the NRMI-2 registry reports,
where door-to-balloon time was 2 h (32,33). Only 8% of
patients in the NRMI-2 registry (33) were treated with
PTCA within 1 h, and accelerated alteplase was the
predominant fibrinolytic agent.
The GUSTO-IIb PTCA substudy (34) is the only
prospective randomized comparison of accelerated alteplase
dosing versus PTCA. No difference in outcome was seen for
six days, suggesting that the small treatment benefit with
PTCA at 30 days was due to reduced reocclusion rates
rather than to better reperfusion rates.
Despite claims by some that higher patency rates
achieved with PTCA will result in better outcomes and thus
justify delaying treatment until it can be performed, several
recent reports have clearly shown that delayed PTCA is
associated with decreased myocardial salvage and increased
mortality rates (33,35,36), just as with fibrinolytic therapy.
Nevertheless, studies in the Netherlands, Denmark, France,
and the Czech Republic are testing the strategies of delayed
reperfusion with transfer to a tertiary-care hospital for
PTCA versus immediate fibrinolysis in community hospi-
tals. An attempt to test this hypothesis in the U.S. was
aborted after three years because of poor patient recruitment
(37). There was a 100-min delay in time to treatment with
PTCA and no difference in outcome.
Study limitations. First, this study included only patients
with ST-segment elevation who were treated with fibrino-
lytic therapy. These results may not apply to patients not
receiving fibrinolytic therapy, where the immediate avail-
ability of reperfusion therapy with PTCA could offer an
advantage. However, previous studies including patients
with ST-segment depression or PTCA treatment availabil-
ity found no survival advantage at hospitals with coronary
revascularization capability (4,14–19). Neither does our
study evaluate whether immediate referral for primary or
facilitated PTCA is a better reperfusion strategy. Second,
this analysis is based on a post-hoc review of a study
enrolling patients from 1990 to 1992. However, recent
innovations including newer fibrinolytic agents (38,39),
newer antithrombotic agents in combination with fibrino-
lytic agents (40,41), and coronary stents (42,43) have not
been shown to further reduce mortality from MI. Third,
even with over 25,000 patients, the power to detect a
significant difference in outcome is low, especially in light of
potential unmeasured confounding factors. The 0.6% higher
mortality rate at 30 days in hospitals without revasculariza-
tion facilities, while not statistically significant at a p 0.01
level after adjustment for baseline differences, includes the
possibility of as much as an 18% relative reduction in
mortality within the 95% confidence interval. Fourth, al-
though we have used multivariable modeling to adjust for
baseline risk, the results of this type of observational study
may be confounded by unmeasured variables. With this
limitation and the retrospective observational nature of this
analysis, our results should be considered hypothesis gener-
ating rather than conclusive. Finally, these results do not
apply to patients in cardiogenic shock, where emergency
PTCA has been shown to reduce mortality (44). Appropri-
ate patients in cardiogenic shock should be transferred
immediately to hospitals capable of performing PTCA and
CABG.
Conclusions. This study suggests similar outcomes for
patients treated with fibrinolytic therapy at hospitals with
and without coronary revascularization capability, provided
that appropriate candidates receive aspirin and beta-
blockers, and that transfer is available for angiography and
coronary revascularization as needed.
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